162 related articles for article (PubMed ID: 86474)
1. Profiles of serum complement in patients with hepatobiliary diseases.
Potter BJ; Elias E; Fayers PM; Jones EA
Digestion; 1978; 18(5-6):371-83. PubMed ID: 86474
[TBL] [Abstract][Full Text] [Related]
2. Complement activation in chronic liver disease.
Munoz LE; De Villiers D; Markham D; Whaley K; Thomas HC
Clin Exp Immunol; 1982 Mar; 47(3):548-54. PubMed ID: 7083631
[TBL] [Abstract][Full Text] [Related]
3. Serum complement in chronic liver disease.
Potter BJ; Trueman AM; Jones EA
Gut; 1973 Jun; 14(6):451-6. PubMed ID: 4737028
[TBL] [Abstract][Full Text] [Related]
4. Differences between plasma and serum complement in patients with chronic liver disease.
Inai S; Kitamura H; Fujita T; Kojima J; Nagaki K
Clin Exp Immunol; 1976 Sep; 25(3):403-9. PubMed ID: 963909
[TBL] [Abstract][Full Text] [Related]
5. The complement system in uremia.
Jørgensen KA; Stoffersen E
Scand J Urol Nephrol; 1980; 14(3):279-82. PubMed ID: 6908167
[TBL] [Abstract][Full Text] [Related]
6. Profiles of antinuclear antibodies in chronic active hepatitis, primary biliary cirrhosis and alcoholic liver disease.
Kurki P; Gripenberg M; Teppo AM; Salaspuro M
Liver; 1984 Apr; 4(2):134-8. PubMed ID: 6610088
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of C3b-binding in chronic liver diseases.
Hautanen A; Salaspuro MP
Scand J Gastroenterol; 1981; 16(4):505-12. PubMed ID: 7323688
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of immunoglobulins and complement components in patients with recurrence after resection of gastric carcinoma.
Janssen CW; Tønder O; Matre R
Cancer Detect Prev; 1987; 10(3-4):303-9. PubMed ID: 3568028
[TBL] [Abstract][Full Text] [Related]
9. [Activity of total complement and concentration of its components C1q, C3, C4 and C1-inactivator in cancer].
Matoses Cuquerella S; O'Connor Miquel C; Lluch Hernández AM; García-Conde Bru J
Med Clin (Barc); 1988 Dec; 91(20):769-74. PubMed ID: 3266280
[No Abstract] [Full Text] [Related]
10. [Complement hemolytic activity (CH50), C3 and C4 levels in serum and plasma of the patients with various liver diseases (author's transl)].
Fujiwara S
Nihon Shokakibyo Gakkai Zasshi; 1981 Feb; 78(2):190-9. PubMed ID: 6264183
[No Abstract] [Full Text] [Related]
11. Complement levels of C4, C3C, factor B, and C1 inactivator in peripheral and retroplacental blood of parturient women with EPH gestosis.
Zdanowicz A; Jabłońska E; Pietruska Z; Bielecki M
Ann Med Univ Bialyst Pol; 1993; 38(1):60-7. PubMed ID: 7922487
[TBL] [Abstract][Full Text] [Related]
12. The cold activation of the classical complement pathway: The cause of the differences between plasma and serum complement in liver cirrhosis.
Kitamura H; Nagaki K; Inoshita K; Iida K; Inai S
Clin Exp Immunol; 1977 Jan; 27(1):34-7. PubMed ID: 849648
[TBL] [Abstract][Full Text] [Related]
13. Complement factors and acute phase reactants in the Guillain-Barré syndrome.
Tönnessen TI; Nyland H; Aarli JA
Eur Neurol; 1982; 21(2):124-8. PubMed ID: 6920298
[TBL] [Abstract][Full Text] [Related]
14. Yeast opsonisation and complement in children with liver disease. Analysis of 69 cases.
Larcher VF; Wyke RJ; Vergani D; Mowat AP; Williams R
Pediatr Res; 1983 Apr; 17(4):296-300. PubMed ID: 6343990
[TBL] [Abstract][Full Text] [Related]
15. Studies on circulating immune complexes of the liver disease. 4. Clq binding activity.
Arima T; Narumoto J; Shimomura H; Suwaki K; Kunishi K; Yasuhara T; Nagashima H
Gastroenterol Jpn; 1980; 15(1):27-32. PubMed ID: 6153628
[TBL] [Abstract][Full Text] [Related]
16. The effect of aging on complement activity (CH50) and complement protein levels.
Nagaki K; Hiramatsu S; Inai S; Sasaki A
J Clin Lab Immunol; 1980 Jan; 3(1):45-50. PubMed ID: 7381926
[TBL] [Abstract][Full Text] [Related]
17. Stage-related correlations between immunoglobulins and complement components in preoperative sera from patients with gastric carcinoma.
Janssen CW; Tönder O; Matre R
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1601-5. PubMed ID: 6685643
[TBL] [Abstract][Full Text] [Related]
18. Acute hepatitis: significance of changes in complement components.
Charlesworth JA; Lawrence S; Worsdall PA; Roy LP; Boughton CR
Clin Exp Immunol; 1977 Jun; 28(3):496-501. PubMed ID: 891025
[TBL] [Abstract][Full Text] [Related]
19. [The C3, C3 Att and C4 fractions of complement in chronic hepatitis: preliminary data].
Riegler G; Ciotola R; Di Simone A
Boll Soc Ital Biol Sper; 1976 Feb; 52(4):200-3. PubMed ID: 952675
[No Abstract] [Full Text] [Related]
20. A solid-phase antibody capture assay for the measurement of C1-inhibitor consumption in vivo.
Wallace EM; Feighery C; Jackson J
Scand J Clin Lab Invest; 1996 Feb; 56(1):1-9. PubMed ID: 8850166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
